BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 6366124)

  • 1. Histologic conversion in the non-Hodgkin's lymphomas.
    Acker B; Hoppe RT; Colby TV; Cox RS; Kaplan HS; Rosenberg SA
    J Clin Oncol; 1983 Jan; 1(1):11-6. PubMed ID: 6366124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
    Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
    Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
    O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
    J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of combination chemotherapy of non-Hodgkin's lymphoma.
    Schein PS; Chabner BA; Canellos GP; Young RD; Berard C; DeVita VT
    Br J Cancer Suppl; 1975 Mar; 2():465-73. PubMed ID: 1101932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Hodgkin's lymphoma in Manitoba, 1968-77: the impact of chemotherapy.
    Deonarine L; Weinerman BH; MacDougall BK; Kemel S
    Can Med Assoc J; 1982 Apr; 126(7):807-11. PubMed ID: 7042060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
    J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
    López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
    Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
    J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
    Hiddemann W; Unterhalt M; Herrmann R; Wöltjen HH; Kreuser ED; Trümper L; Reuss-Borst M; Terhardt-Kasten E; Busch M; Neubauer A; Kaiser U; Hanrath RD; Middeke H; Helm G; Freund M; Stein H; Tiemann M; Parwaresch R
    J Clin Oncol; 1998 May; 16(5):1922-30. PubMed ID: 9586911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
    Teodorovic I; Pittaluga S; Kluin-Nelemans JC; Meerwaldt JH; Hagenbeek A; van Glabbeke M; Somers R; Bijnens L; Noordijk EM; Peeters CD
    J Clin Oncol; 1995 Nov; 13(11):2819-26. PubMed ID: 7595744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
    Conlan MG; Bast M; Armitage JO; Weisenburger DD
    J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)].
    Parlier Y; Gorin NC; Stachowiak J; Najman A; Duhamel G
    Sem Hop; 1981 Nov 8-25; 57(41-42):1685-90. PubMed ID: 6272402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
    Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
    J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma.
    Davidge-Pitts M; Dansey R; Bezwoda WR
    Leuk Lymphoma; 1997 Jan; 24(3-4):341-7. PubMed ID: 9156664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].
    Chubachi A; Miura AB; Yamaguchi A; Nishimura S
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.
    Tondini C; Zanini M; Lombardi F; Bengala C; Rocca A; Giardini R; Buzzoni R; Valagussa P; Bonadonna G
    J Clin Oncol; 1993 Apr; 11(4):720-5. PubMed ID: 8478665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
    Bennett JM; Lenhard RE; Ezdinli E; Johnson GJ; Carbone PP; Pocock SJ
    Cancer Treat Rep; 1977 Sep; 61(6):1079-83. PubMed ID: 71207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.